C9312 HCPCS code: Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg
C9312 is the HCPCS Level II code for injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2026-10-01 |
| Last action effective | 2026-10-01 |
What changed for C9312
- October 2026: Code appears in this HCPCS release
- 2026-10-01: C9312 added to HCPCS Level II
- 2026-10-01: Last CMS action: code added
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9312?
C9312 is the HCPCS Level II code for injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg. Short descriptor: "Inj trabecte apotex, 0.01 mg".
Does Medicare cover C9312?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Related C93 codes
- C9300 — Injection, indigotindisulfonate sodium, 1 mg
- C9301 — Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9302 — Injection, zanidatamab-hrii, 2 mg
- C9303 — Injection, zolbetuximab-clzb, 1 mg
- C9304 — Injection, marstacimab-hncq, 0.5 mg
- C9305 — Injection, nipocalimab-aahu, 3 mg
- C9306 — Injection, telisotuzumab vedotin-tllv, 1 mg
- C9307 — Injection, linvoseltamab-gcpt, 1 mg
- C9308 — Injection, carboplatin (avyxa), 1 mg
- C9309 — Injection, onasemnogene abeparvovec-brve, per treatment
- C9310 — Injection, leucovorin calcium (avyxa), 1 mg
- C9311 — Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9312
- Watch C9312 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9312
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.